• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2021, Vol. 38 ›› Issue (5): 418-424.

• 药品评价 • 上一篇    下一篇

替罗非班用于颅内动脉瘤围手术期安全性和有效性的Meta分析

 雷迪1, 李兴德2*, 宋沧桑2, 张阳2, 张函舒2   

  1. 1. 大理大学药学院, 云南 大理 671000;
    2. 昆明市第一人民医院药学部, 云南 昆明 650000
  • 收稿日期:2021-06-08 修回日期:2021-07-20 出版日期:2021-10-28 发布日期:2021-10-28
  • 基金资助:
    云南省卫生健康委员会医学领军人才培养计划项目(No.L-2018012);昆明市卫生科技人才培养项目(No.2018-SW(省)-05);昆明市卫生科技人才培养暨技术中心建设项目(No.2018-SW(技)-12);昆明市第六周期临床重点专科(临床药学)建设项目;云南省卫生科技计划项目(No.2018NS0170)

Meta-analysis of Safety and Efficacy of Tirofiban in Perioperative Treatment of Intracranial Aneurysms

  1. 1. College of Pharmaceutical science, Yunnan Dali 671000, China;
    2. University Department of Pharmacy, The First Hospital of Kunming, Yunnan Kunming 650000, China
  • Received:2021-06-08 Revised:2021-07-20 Online:2021-10-28 Published:2021-10-28

摘要: 目的:系统评价替罗非班用于颅内动脉瘤围手术期的安全性和有效性,为临床合理用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、中国生物医学、中国知网、维普、万方数据库,收集不同治疗方式下替罗非班联合或不联合双抗药物(试验组)对比双抗药物(对照组)治疗颅内动脉瘤的临床研究。筛选文献并提取资料,采用Cochrane系统评价随机对照试验(RCT)文献质量,采用纽卡斯尔-渥太华量表评价队列研究文献质量。采用RevMan 5.3软件进行Meta分析。结果:共纳入16项研究,其中8项为RCT,8项为队列研究,共计2 333例患者。Meta分析结果显示,与对照组比较,试验组方案可显著减少血栓栓塞事件[RR=0.43,95%CI(0.31,0.60),P<0.001]、颅内出血事件[RR=0.51,95%CI(0.32,0.83),P=0.007]。两组患者血小板计数比较,差异无统计学意义(P>0.05)。结论:使用替罗非班可有效降低血栓栓塞事件和颅内出血事件风险。对于破裂动脉瘤支架辅助栓塞围手术期使用替罗非班抗血小板治疗是安全和有效的,可作为术前负荷双抗的可行替代方案。
  

关键词: font-size:medium, ">替罗非班;双重抗血小板;颅内动脉瘤;安全性;有效性;Meta分析

Abstract: Objective: To systematically evaluate the efficacy and safety of teicoplanin in the treatment of intracranial aneurysms, and to provide evidence-based reference for clinical rational drug use. Methods: The Cochrane Library, PubMed, Embase, Chinese Biomedical, Chinese Knowledge Infrastructure, VIP, and Wanfang databases were searched by computer to collect clinical studies on the treatment of intracranial aneurysms with tirofiban with or without dual antibody drugs (experimental group) versus dual antibody drugs (control group) under different treatment modalities. The literature was screened and extracted, the Cochrane systematic review randomized controlled trial (RCT) literature quality was used, and the Newcastle-Ottawa scale was used to evaluate the cohort study literature quality. Meta-analysis was performed using RevMan 5.3 software. Results: A total of 16 studies were included, of which 8 were RCTs and 8 were cohort studies in 2 333 patients. Meta-analysis results showed that compared with the control group, the experimental group protocol can significantly reduce thromboembolic events [RR=0.43,95%CI(0.31,0.60), P<0.001], intracranial hemorrhage events [RR=0.51,95%CI( 0.32, 0.83), P=0.007]. There was no significant difference in platelet count between the two groups of patients (P>0.05). Conclusion: The use of tirofiban can effectively reduce the risk of thromboembolic events and intracranial hemorrhage events. The perioperative use of tirofiban antiplatelet therapy for ruptured aneurysm stent-assisted embolization is safe and effective, and it can be used as a viable alternative to preoperative loading of double antibodies.

Key words: font-size:medium, ">Tirofiban; DAPT; Intracranial aneurysm; Safety; Efficacy; Meta-analysis

中图分类号: